AbbVie Inc. (ABBV)
AbbVie Inc. (ABBV) from its SEC filings: 2025 revenue $61.2 billion (+9% vs the year before), net margin 7%, free cash flow $17.8 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $61.2 billion |
| Revenue growth | +9% |
| Net income | $4.2 billion |
| Net margin | 6.9% |
| Free cash flow | $17.8 billion |
| Diluted EPS | $2.36 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +10% |
| Cash | $6.6 billion |
| Long-term debt | $64.5 billion |
| Share count, 1 year | +0% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.